Sunday 20th May, 2012   |   Welcome, guest. Please, login or register  
Sunday October 18, 00:22

Cervarix vaccine, licensed in the United States and Japan

Laboratory GlaxoSmithKline
Laboratory GlaxoSmithKline
 

The authority of American medicine, the Food and Drug Administration (FDA) authorized the sale of Cervarix in the United States, to vaccinate girls and young women aged 10 to 25 years.

Following approval from the FDA, GSK expects to begin distributing the Cervarix to the U.S. market towards the end of the year.

GSK's vaccine protects against types 16 and 18 of HPV responsible for cervical cancer.

This authorization is a great relief for the British group, which will have to work extra hard to catch up on the U.S. market against the Gardasil.

This vaccine competitor, manufactured by the American Merck and Sanofi Pasteur, the vaccines department of the European laboratory Sanofi-Aventis, which also protects types 6 and 11 virus is in fact authorized since June 8, 2006 in the United States .

This Friday, GSK has announced two more good news for its vaccines business. The Cervarix became the first vaccine against cervical cancer of the uterus have been approved by health authorities in Japan.

Some 3,500 Japanese die now of the disease each year and the number is growing, particularly among women 20 to 39 years for which it is the leading cause of cancer in the country.

With the green lights unhooked the United States and Japan, Cervarix is now permitted in a hundred countries, according to a tally conducted by the manufacturer. This includes the 27 member states of the European Union, Australia, Brazil, South Korea, Mexico and Taiwan.

Finally, good news, GSK said Friday that the results of the second clinical trial of its vaccine against influenza A (H1N1), the Pandemrix, made in Belgium, confirmed that it was effective with the first dose, as was already shown by the first test.

 
Rate:
  •  
Please, login to rate the article.
 
 

Recommended articles:

 

H1N1: availability of vaccines in the U.S., after delays

Although it is too difficult to get vaccines, they become much more available
The number of vaccines against H1N1 influenza available in the United States is on the increase, said Tuesday U.S. health officials
 

An H1N1 vaccine as nasal spray in the U.S.

Vaccination against the H1N1 virus, based on FluMist, at a school in Miami (Florida)
FluMist is well accepted overseas, but has not been approved in Europe yet.
 

24 million children have no access to vaccines

Vaccination rates are now at their highest level, even if millions of children remain excluded from this progress, particularly in the poorest countries
24 million children from the poorest countries have no access to vaccines, according to a report by the World Health Organization (WHO), UNICEF and the World Bank.
 

Most recent in the category Cancer:

 
 
 

Last comments

 

No comments. Be the first to comment the article!

Please, login to post comments.
 
 
 
 

Home | Social Health | AIDS | Cancer | Deseases | Diet | Human body | Most read | Top rated

RSS | Feedback | Headlines for your website | Terms of Service/Privacy policy

Copyright © 2012 Heal-all.org. All rights reserved.